ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
ARS Pharmaceuticals (Nasdaq: SPRY), a company focused on protecting people from severe allergic reactions, announced its participation in the 2024 Wedbush PacGrow Healthcare Conference. The event will take place on August 13-14, 2024 in New York City. Company management will meet with investors on Wednesday, August 14, 2024, for one-on-one discussions.
This conference provides ARS Pharmaceuticals with an opportunity to showcase its work in empowering at-risk patients and caregivers against anaphylaxis. The company's presence at this healthcare-focused event could potentially attract investor interest and highlight its position in the biopharmaceutical sector.
ARS Pharmaceuticals (Nasdaq: SPRY), un'azienda focalizzata sulla protezione delle persone da reazioni allergiche gravi, ha annunciato la sua partecipazione alla 2024 Wedbush PacGrow Healthcare Conference. L'evento si terrà dal 13 al 14 agosto 2024 a New York City. La direzione dell'azienda incontrerà gli investitori mercoledì 14 agosto 2024, per discussioni in incontri individuali.
Questa conferenza offre ad ARS Pharmaceuticals un'opportunità per mettere in mostra il suo impegno nell'emancipazione dei pazienti e dei caregiver a rischio contro l'anafilassi. La presenza dell'azienda a questo evento focalizzato sulla sanità potrebbe potenzialmente attirare l'interesse degli investitori e mettere in evidenza la sua posizione nel settore biofarmaceutico.
ARS Pharmaceuticals (Nasdaq: SPRY), una empresa enfocada en proteger a las personas de reacciones alérgicas graves, anunció su participación en la 2024 Wedbush PacGrow Healthcare Conference. El evento se llevará a cabo del 13 al 14 de agosto de 2024 en la ciudad de Nueva York. La dirección de la empresa se reunirá con los inversores el miércoles 14 de agosto de 2024, para discusiones uno a uno.
Esta conferencia ofrece a ARS Pharmaceuticals la oportunidad de mostrar su trabajo en empoderar pacientes y cuidadores en riesgo frente a la anaflaxia. La presencia de la empresa en este evento centrado en la salud podría atraer potencialmente el interés de los inversores y destacar su posición en el sector biofarmacéutico.
ARS Pharmaceuticals (Nasdaq: SPRY)는 심각한 알레르기 반응으로부터 사람들을 보호하는 데 초점을 맞춘 회사로, 2024 Wedbush PacGrow Healthcare Conference에 참여한다고 발표했습니다. 이 행사는 2024년 8월 13일부터 14일까지 뉴욕시에서 열릴 예정입니다. 회사의 경영진은 2024년 8월 14일 수요일에 투자자들과 개별적으로 면담할 것입니다.
이번 컨퍼런스는 ARS Pharmaceuticals가 아나필락시스에 대한 위험이 있는 환자와 보호자를 지원하는 작업을 선보일 수 있는 기회를 제공합니다. 이 회사의 건강 관련 행사 참여는 투자자의 관심을 끌고 생물제약 분야에서의 입지를 강조할 수 있는 잠재적인 기회를 제공할 수 있습니다.
ARS Pharmaceuticals (Nasdaq: SPRY), une entreprise axée sur la protection des personnes contre les réactions allergiques sévères, a annoncé sa participation à la 2024 Wedbush PacGrow Healthcare Conference. L'événement se déroulera du 13 au 14 août 2024 à New York. La direction de l'entreprise rencontrera des investisseurs le mercredi 14 août 2024, pour des discussions individuelles.
Cette conférence offre à ARS Pharmaceuticals l'occasion de mettre en avant son travail pour autonomiser les patients et les aidants à risque face à l'anaphylaxie. La présence de l'entreprise à cet événement axé sur la santé pourrait potentiellement attirer l'intérêt des investisseurs et mettre en lumière sa position dans le secteur biopharmaceutique.
ARS Pharmaceuticals (Nasdaq: SPRY), ein Unternehmen, das sich darauf konzentriert, Menschen vor schweren allergischen Reaktionen zu schützen, hat seine Teilnahme an der 2024 Wedbush PacGrow Healthcare Conference bekannt gegeben. Die Veranstaltung findet am 13. und 14. August 2024 in New York City statt. Die Unternehmensleitung wird am Mittwoch, den 14. August 2024, Treffen mit Investoren für Einzelgespräche führen.
Diese Konferenz bietet ARS Pharmaceuticals die Möglichkeit, seine Bemühungen zur Stärkung gefährdeter Patienten und Pflegekräfte im Umgang mit Anaphylaxie vorzustellen. Die Präsenz des Unternehmens bei dieser gesundheitsorientierten Veranstaltung könnte möglicherweise das Interesse von Investoren wecken und seine Position im biopharmazeutischen Sektor hervorheben.
- None.
- None.
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Wedbush PacGrow Healthcare Conference being held August 13-14, 2024 in New York City. Company management will participate in one-on-one meetings with investors on Wednesday, August 14, 2024.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.
ARS Investor Contacts:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com
ARS Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com
FAQ
When is ARS Pharmaceuticals (SPRY) participating in the Wedbush PacGrow Healthcare Conference?
Where is the 2024 Wedbush PacGrow Healthcare Conference being held?
What is the focus of ARS Pharmaceuticals (SPRY)?
How will ARS Pharmaceuticals (SPRY) engage with investors at the conference?
